氯丙咪嗪,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
689	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a normal or increased function allele may have increased metabolism of clomipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.
688	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.
687	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.
686	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with another normal function allele may have increased metabolism of clomipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of clomipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.

等位基因

注释文本

The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of clomipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.

688

The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.

687

The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of clomipramine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.

686

The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of clomipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of clomipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2C19 and clomipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of clomipramine.

id	证据的ID	总结
672	1448631821	CYP2C19 1/2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.
671	1446903149	CYP2C19 17 + 2 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2C19 1/1.
670	1446903139	CYP2C19 2/2 is associated with decreased metabolism of clomipramine in people with Mental Disorders as compared to CYP2C19 1/1.
669	1183616544	CYP2C19 3 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 1/*1.
668	1183616535	CYP2C19 2 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 1/*1.
667	1446906755	CYP2C19 poor metabolizers are associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizers.
666	PA166184528	Annotation of DPWG Guideline for clomipramine and CYP2C19
665	PA166105007	Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6

证据的ID

总结

672

1448631821

CYP2C19 *1/*2 is associated with increased trough concentration of clomipramine and desmethyl clomipramine.

671

1446903149

CYP2C19 *17 + *2 are not associated with concentrations of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.

670

1446903139

CYP2C19 *2/*2 is associated with decreased metabolism of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.

669

1183616544

CYP2C19 *3 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.

668

1183616535

CYP2C19 *2 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.

667

1446906755

CYP2C19 poor metabolizers are associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizers.

666

PA166184528

Annotation of DPWG Guideline for clomipramine and CYP2C19

665

PA166105007

Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6

id	类型	评论
931	Update	Added DPWG guideline.
930	Update	CA score added as part of scoring system release. LOE assigned following curator review.
929	Update	changed LOE to 1A because of CPIC guideline; changed to allele description and PK evidence only; combined with 982038133 (*2 rsID CA)

类型

931

Update

Added DPWG guideline.

930

Update

CA score added as part of scoring system release. LOE assigned following curator review.

929

Update

changed LOE to 1A because of CPIC guideline; changed to allele description and PK evidence only; combined with 982038133 (*2 rsID CA)